

NCCN Hodgkin Lymphoma V.3.2011 – Teleconference – 09/08/11

| Guideline Page and Request | Panel Discussion | References | Vote | | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----|---------|
| | | | YES | NO | ABSTAIN |
| <p>HODG-11</p> <p>Internal request: Review the data for brentuximab vedotin for inclusion in the relapsed or refractory setting.</p> <p>External request: Submission from Seattle Genetics, Inc for inclusion of brentuximab vedotin for patients with progressive disease or relapse.</p> | <p>Based upon the data noted in the references for brentuximab vedotin in relapsed or refractory Hodgkin lymphoma, the panel consensus was to add brentuximab vedotin as a treatment option for patients with relapsed or progressive disease, who have failed HDT/ASCR or at least 2 prior multi-agent chemotherapy regimens.</p> | <p>Chen R, Gopal AK, Smith SE, et al. Results from a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma. Poster session presented at: 2011 ASCO Annual Meeting; 2011 June 3-7; Chicago, IL .</p> <p>http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstr actID=76520</p> <p>Prescribing information for brentuximab vedotin. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125388s000,125399s000lbl.pdf</p> | 18 | 0 | 0 |